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Abstract
Background: Traditionally, hyperbaric oxygen treatment (HBOT) has been used to treat a limited repertoire of
disease, including decompression sickness and healing of problem wounds. However, some investigators have
used HBOT to treat inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis.
Methods: Comprehensive searches were conducted in 8 scientific databases through 2011 to identify publications
using HBOT in IBD. Human studies and animal models were collated separately.
Results: Thirteen studies of HBOT in Crohn’s disease and 6 studies in ulcerative colitis were identified. In all studies,
participants had severe disease refractory to standard medical treatments, including corticosteroids, immunomodulators
and anti-inflammatory medications. In patients with Crohn’s disease, 31/40 (78%) had clinical improvements with HBOT,
while all 39 patients with ulcerative colitis improved. One study in Crohn’s disease reported a significant decrease in
proinflammatory cytokines (IL-1, IL-6 and TNF-alpha) and one study in ulcerative colitis reported a decrease in IL-6 with
HBOT. Adverse events were minimal. Twelve publications reported using HBOT in animal models of experimentally-
induced IBD, including several studies reporting decreased markers of inflammation or immune dysregulation, including
TNF-alpha (3 studies), IL-1beta (2 studies), neopterin (1 study) and myeloperoxidase activity (5 studies). HBOT also
decreased oxidative stress markers including malondialdehyde (3 studies) and plasma carbonyl content (2 studies),
except for one study that reported increased plasma carbonyl content. Several studies reported HBOT lowered nitric
oxide (3 studies) and nitric oxide synthase (3 studies) and one study reported a decrease in prostaglandin E2 levels. Four
animal studies reported decreased edema or colonic tissue weight with HBOT, and 8 studies reported microscopic
improvements on histopathological examination. Although most publications reported improvements with HBOT,
some studies suffered from limitations, including possible publication and referral biases, the lack of a control group, the
retrospective nature and a small number of participants.
Conclusions: HBOT lowered markers of inflammation and oxidative stress and ameliorated IBD in both human and
animal studies. Most treated patients were refractory to standard medical treatments. Additional studies are
warranted to investigate the effects of HBOT on biomarkers of oxidative stress and inflammation as well as clinical
outcomes in individuals with IBD.
Keywords: Hyperbaric oxygen treatment, Inflammation, Oxidative stress, Inflammatory bowel disease, Crohn?’?s dis-
ease, Ulcerative colitis, Biomarkers
Background
Inflammatory bowel disease (IBD) is a chronic inflam-
matory disease of the gastrointestinal (GI) tract charac-
terized by chronic and recurrent ulcerations [1], and
includes Crohn’s disease and ulcerative colitis. IBD is
usually accompanied by severe GI symptoms such as
diarrhea, bleeding, abdominal pain, weight loss, and ane-
mia. The symptoms of IBD can be intermittent, with
periods of exacerbations and periods that may be rela-
tively free of symptoms. Recent evidence suggests that
the pathophysiology of IBD involves immune dysregula-
tion, genetic susceptibilities, intestinal barrier dysfunc-
tion, and alterations in microbial flora [2]. Activated
macrophages appear to play a key role in the disease
process and produce proinflammatory cytokines,
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Intestinal nitric oxide (NO) levels are also increased in
some patients with IBD which may lead to increased
intestinal tissue injury [4]. Oxidative stress and mito-
chondrial dysfunction are also found in some patients
with IBD [5,6]. Some investigators have reported that
certain infections such as Mycobacterium avium subspe-
cies paratuberculosis may also play a role in IBD [7].
Interestingly, decreased blood flow to the rectum has
been reported in some individuals with ulcerative colitis
[8].
Current medical treatments for IBD are aimed at
maintaining clinical remission and include biologic
therapies (e.g., monoclonal antibodies), immunomodula-
tors, aminosalicylates, corticosteroids and other anti-
inflammatory modalities [9]. Several studies have
reported improvements using hyperbaric oxygen treat-
ment (HBOT) in some patients with IBD [10-12].
HBOT involves inhaling 100% oxygen at greater than
one atmosphere absolute (ATA) in a pressurized cham-
ber [13]. HBOT has been used successfully in humans
at varying pressures to treat a range of conditions. Many
clinical applications of HBOT are at higher pressures (e.
g., 2.0 ATA and above) including treatment of decom-
pression sickness, arterial gas embolism, and carbon
monoxide poisoning [14]. HBOT has been shown to
increase the oxygen content of plasma [15] and body tis-
sues [16] and may normalize oxygen levels in ischemic
tissues [17]. Recently, evidence has accumulated that
HBOT also has potent anti-inflammatory effects [18-20].
This manuscript is a systematic review and analysis of
the medical literature concerning the use of HBOT in
IBD.
Methods
Search strategy
A search of the Pubmed, EMBASE, Google Scholar,
CINAHL, ERIC, AMED, PsychInfo, and Web of Science
databases from their inception through December 31,
2011 was conducted to identify and collate pertinent
publications using the search terms “hyperbaric oxygen”,
“HBOT”, “hyperbaric” in all combinations with “IBD”,
“inflammatory bowel”, “inflammatory bowel disease”,
“colitis”, “ulcerative colitis”, “Crohn”, “Crohn’s”, “esopha-
gitis”, “gastritis”, “duodenitis”, “jejunitis”, “ileitis”,a n d
“proctitis.” Figure 1 demonstrates the flow chart of pub-
lications identified by the literature search.
Study selection
Publications were initially included if they: (1) involved
individuals or specimens from individuals with IBD
(including Crohn’s disease and ulcerative colitis) or were
animal models of IBD, and (2) reported using HBOT.
Abstracts of identified publications were reviewed to
determine if a publication should be included. If the
abstract was obscure or missing, the publication was
reviewed to determine if inclusion was warranted. Publi-
cations of animal models were collated separately. Stu-
dies of gastrointestinal abnormalities caused exclusively
by radiation treatment were excluded (36 studies). Stu-
d i e sn o tw r i t t e ni nE n g l i s h( 9s t u d i e s )[ 2 1 - 2 9 ]w e r e
excluded (unless an English abstract was available). Stu-
dies that were purely review articles (4 studies) [30-33]
or letters to the editor (3 publications) [34-36] that did
not present any new or unique data were also excluded.
Finally, studies that published repeated data and not
new or unique data (2 studies) [37,38] were excluded.
Results
Publications identified by the search
A total of 466 publications were identified. After 233
duplicates were removed, 233 publications were exam-
ined. Studies meeting inclusion criteria included 13 pub-
lications on the use of HBOT in Crohn’sd i s e a s e ,6o n
ulcerative colitis and 12 on animal models of IBD.
Studies on Crohn’s disease
Table 1 outlines the 13 studies [10,11,39-49] meeting inclu-
sion criteria that reported the use of HBOT in Crohn’sd i s -
ease. Six studies were prospective [10,41-43,47,49] and one
contained a control group [49]. In each of the 13 studies,
the patients had severe Crohn’s disease that was refractory
to standard medical treatments, including, in some cases,
corticosteroids, sulfasalazine, metronidazole, 6-mercapto-
purine, and an elemental diet. One study reported improve-
ments with a stay of up to 3 weeks at the Dead Sea
(equivalent to 1.05 ATA) in 6 patients [42]. Two studies
Figure 1 Flow diagram of studies.
Rossignol Medical Gas Research 2012, 2:6
http://www.medicalgasresearch.com/content/2/1/6
Page 2 of 11Table 1 Studies of HBOT in Crohn’s disease
Author,
year,
country
Type of
study
Number of
patients
improved/
number
treated
Location
of
Crohn’s
HBOT parameters Side effects Comments/outcomes
Brady et al.
1989 [39],
USA
Case report 1/1 Perineal,
cutaneous
2.4 ATA 100% oxygen; 6 days a
week; 2 h sessions; 67 total
sessions
Blurred vision,
resolved
Crohn’s disease was refractory to
surgery and medical treatment
(corticosteroids, sulfasalazine,
metronidazole, and 6-mercaptopurine)
for 8 years; complete and dramatic
healing in 2.5 months with HBOT;
patient needed additional HBOT over 11
months, then had lasting improvements
Brady 1993
[40], USA
Letter to
editor/case
report
1/1† Perineal,
cutaneous
Not reported, but presumably
the same as previous report
(Brady et al. 1989) [39]
NR Update on patient from previous case
report (Brady et al. 1989) [39]. Patient
had two additional courses of HBOT (29
and 26 sessions) and was in remission
for over 3 years at time of letter
Colombel
et al. 1995
[41],
France
Prospective,
uncontrolled
6/10 Perineal 2.5 ATA 100% oxygen; 2 sessions
per day; 5 sessions per week; 40
planned sessions over 4 weeks; 8
patients completed at least 30
treatments
1 patient had
bilateral ear drum
perforation;
another had
psychological
intolerance
All patients had severe Crohn’s disease
and had failed one or more standard
medical treatments; 2 patients stopped
treatments after a few sessions due to
side effects; 6 of 8 fully treated patients
had partial or complete healing
Fraser and
Niv 1995
[42], Israel
Prospective,
uncontrolled
6/6 Perianal;
ileocolonic
Equivalent to 1.05 ATA NR 6 patients with Crohn’s disease
unresponsive to standard medical
treatments spent up to 3 weeks at the
Dead Sea; significant healing noted in
all 6 patients
Iezzi et al.
2011 [43],
Brazil
Prospective,
uncontrolled
11/14 Perineal or
cutaneous
2.4 ATA; 2 h sessions; 1 session
per day; 10-50 total sessions
NR Patients had Crohn’s disease refractory
to standard medical treatments; 11 of
14 (79%) had “satisfactory improvement”
(complete or partial improvement) with
HBOT
Jiang et al.
2000 [44],
USA
Case report 1/1 ileocolonic 2.5 ATA 100% oxygen; 90 min
sessions; 28 day duration
NR Patient had Crohn’s disease and
Fournier gangrene; good outcome with
surgery, medication and HBOT
Kiel et al.
2011 [45],
Australia
Case report 1/1 Cecal NR NR Patient had Crohn’s disease and
Clostridium septicum infection, treated
with antibiotics and HBOT
postoperatively with improvements
noted
Lavy et al.
1994 [10],
Israel
Prospective,
uncontrolled
8/10 Perianal 2.5 ATA 100% oxygen; 90 min
sessions; 6 times per week; 20
total treatments; HBOT could be
repeated for total of 40 sessions
none 10 patients with Crohn’s disease
refractory to standard medical
treatments; improvement observed in 8
of 10 patients; 6 patients had complete
healing
Nelson et
al. 1990
[46], USA
Case report 1/1 Perineal 2.0-2.8 ATA; 90-120 min sessions;
total of 62 sessions
NR Patient had severe refractory Crohn’s
disease (failed sulfasalazine and
corticosteroids), complete healing with
HBOT; no reoccurrence in 24 months
after HBOT
Saglam et
al. 2008
[47],
Turkey
Prospective,
uncontrolled
14, 2 had
Crohn’s
disease
NR 2.5 ATA; 90 min sessions; 1
treatment per day
NR Study measured flow-mediated
vasodilation of brachial artery; clinical
outcomes of HBOT on GI abnormalities
in 2 patients with Crohn’s disease not
reported
Sipahi et
al. 1996
[48], Brazil
Case report 1/1 Perianal 2.4 ATA; 90 min sessions; 7 times
per week (1
st 2 weeks) then 3
times per week; 45 total sessions
over 3 months
NR Complete healing of perianal Crohn’s
disease with HBOT and antibiotics
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data on these patients [40,49]. One study reported the
effects of HBOT on flow-mediated vasodilation of the bra-
chial artery in 2 patients with Crohn’s disease, but did not
report the clinical outcomes of HBOT on gastrointestinal
inflammation in these patients [47]. The remaining 9 stu-
dies [10,11,39,41,43-46,48] totaled 40 unique patients with
Crohn’s disease who were treated with HBOT ranging from
2.0 to 2.8 ATA. Of these 40 patients, 31 (78%) had clinical
improvements in Crohn’s disease with HBOT. One study
reported a significant decrease in proinflammatory cyto-
kines (IL-1, IL-6 and TNF-a) after HBOT in 7 patients
with Crohn’s disease [49].
Studies on ulcerative colitis
Table 2 outlines the 6 studies [12,50-54] meeting inclu-
sion criteria that reported the use of HBOT in ulcerative
colitis. In each study, the patients had severe ulcerative
colitis that was refractory to standard medical treat-
ments, including, in some cases, corticosteroids, 6-mer-
captopurine, mesalamine, tetracycline, 5-amino salicylic
acid, and azathioprine. One case series [50] reported
two patients with ulcerative colitis who improved with
HBOT; one of these patients had previously been
reported [52]. One study from Bulgaria was not pub-
lished in English, except for the abstract which reported
that 34 patients with chronic ulcerohemorrhagic colitis
had improvements with HBOT [53]; however, since only
the abstract was written in English, the strengths and
weaknesses of this study could not be adequately
assessed. The remaining 5 studies [12,50-52,54] totaled
5 unique patients with all 5 reported as having improve-
ments in ulcerative colitis with HBOT; each patient was
treated at 2.0 ATA. One study reported a decrease in
the IL-6 concentration with HBOT [54].
Adverse events in Crohn’s disease and ulcerative colitis
Of the 13 studies in Crohn’s disease, 10 did not report if
there were any adverse events [11,40,42-49]. One study
reported that one patient had a bilateral ear drum per-
foration and another had psychological intolerance; both
patients had to stop HBOT after a few sessions [41]. It
should be noted that ear drum perforation and psycholo-
gical intolerance are related to changes in pressure and
confinement and not side effects of the oxygen being
administered. Another study reported blurred vision in
one patient which resolved spontaneously [39]. The final
study in Crohn’s disease specifically reported that there
were no adverse events [10]. Of the 6 studies in ulcerative
colitis, 3 studies did not report if there were any adverse
events [12,51,53] while 3 studies specifically reported that
there were no adverse events [50,52,54].
Studies of animal models of IBD
Table 3 outlines the 12 studies [55-66] meeting inclusion
criteria that reported the use of HBOT in experimentally-
induced colitis in an animal model of IBD. All 12 studies
used rats as the animal model. One study was published
only in abstract form [62] and another study was not pub-
lished in English except for the abstract [65]. Most studies
were published in Turkey except for two studies published
in the United States [63,66] and one in Israel [64]. Several
studies reported that HBOT reduced markers of inflam-
mation, including TNF-alpha [61,63,66], IL-1b [63,66] and
neopterin levels [56]. HBOT also decreased edema or
colonic tissue weight in 4 studies [56,57,62,64]. One study
reported HBOT was equivalent in anti-inflammatory effect
to dexamethasone [57]. Myeloperoxidase activity (an index
of the accumulation of neutrophils) was reduced after
HBOT in 5 studies [55,57,63,64,66]. Some studies reported
that HBOT lowered markers of oxidative stress, including
malondialdehyde [56,60,61] and plasma carbonyl content
[55,61], except for one study that reported HBOT
increased protein carbonyl content [65]. Two studies
reported HBOT significantly increased glutathione peroxi-
dase and superoxide dismutase levels [60,61]. HBOT also
decreased nitric oxide [58,61,63] and nitric oxide synthase
levels [63,64,66]. Finally, in one study, HBOT decreased
Table 1 Studies of HBOT in Crohn?’?s disease (Continued)
Takeshima
et al. 1999
[11], Japan
Case report,
letter to
editor
1/1 Colonic,
rectal
2.8 ATA 100% oxygen; 120 min
sessions; 20 total sessions
NR Patient had refractory Crohn’s disease
(failed prednisolone, sulfasalazine and
elemental diet); complete healing of
rectal ulcer (by endoscopic examination)
with HBOT; clinical remission for 7
months at time of publication
Weisz et
al. 1997
[49], Israel
Prospective,
controlled
(10 healthy
controls)
5/7† [same
patients as
(Lavy et al.
1994)] [10]
Perianal 2.5 ATA 100% oxygen; 90 min
sessions; 20-40 total sessions
NR Complete healing in 3 patients after 20
sessions and in 2 patients after 40
sessions; partial improvements observed
in remaining 2 patients.
Proinflammatory cytokines significantly
decreased during HBOT (IL-1, p < 0.01;
IL-6, p < 0.05; TNF-a, p < 0.05)
NR not reported
† contained patient(s) from a previous study
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ogy scores to document changes with HBOT [55-61,64,65]
and 8 reported microscopic improvements [56-61,64,65].
Discussion
Crohn’s disease and ulcerative colitis are forms of IBD
which have a limited repertoire of treatment options.
Management consists of maintaining clinical remission.
In the reviewed studies, HBOT was associated with
improvements in most treated patients. Of note, all of
the patients in these studies had IBD that was refractory
to standard medical treatments and HBOT was essen-
tially used as a treatment of last resort. Adverse events
were minimal in most studies. Several animal studies
reported that HBOT decreased inflammation and oxida-
tive stress markers and led to improvements in IBD on
both a microscopic and macroscopic level.
Effects of HBOT on inflammation and immune
dysregulation in IBD
IBD is characterized by inflammation, ulcerations and the
accumulation of neutrophils. Many of the reviewed animal
models replicated IBD by inducing colitis which was
accompanied by intestinal edema, ulcerations, accumula-
tion of neutrophils, increased nitric oxide levels and ele-
vated cytokines. Therefore, these animal models appeared
effective at reproducing the pathophysiology of IBD.
HBOT has been shown to possess potent anti-inflam-
matory properties in both animal [55,67,68] and human
studies [10,11,20,46,69] and has been reported to
decrease the production of pro-inflammatory cytokines
(such as TNF-alpha, interferon-gamma, IL-1 and IL-6)
in both animal [66,70] and human studies [20,49] as
well as increase IL-10 levels [71]. Several of the reviewed
studies (including human studies and animal models)
reported a decrease in inflammation as measured by
reduced tissue edema and histopathological changes, as
well as a decrease in TNF-alpha, IL-1 and IL-6 with
HBOT [49,54,61,63,66]. Some of these effects may have
been mediated, to some degree, by the activity of stem
cells [72]. Stem cells have been shown to migrate to the
sites of inflammation and damage [73]. Several studies
have reported that HBOT can stimulate the growth and
differentiation of stem cells [74-78] as well as mobilize
Table 2 Studies of HBOT in ulcerative colitis
Author,
year,
country
Type of
study
Number of
patients
improved/number
treated
HBOT parameters Side
effects
Comments/outcomes
Buchman et
al. 2001 [12],
USA
Case
report
1/1 2.0 ATA 100% oxygen; 2 h
duration; 5 days per week;
30 total treatments
NR Pancolonic ulcerative colitis refractory to conventional
medical treatments (corticosteroids for 22 months, 6-
mercaptopurine, mesalamine and tetracycline); significant
improvements and clinical remission with HBOT (effect
lasted 2 months)
Demirturk et
al. 2002 [50],
Turkey
Case
series†
2/2; one from
(Hulagu et al. 1997)
[52]
2.0 ATA 100% oxygen; 2 h
duration; 30 days of
treatment
none Pancolitis in 2 patients with ulcerative colitis was refractory
to standard medical treatments (mesalamine and
prednisolone); in the first patient during the third week of
HBOT, significant improvements were observed; in second
patient, improvements observed within 2 weeks;
resolution of bloody diarrhea noted in both cases
Gurbuz et al.
2003 [51],
Turkey
Case
report;
letter to
editor
1/1 2.0 ATA 100% oxygen; 2 h
duration; 35 days of
treatment
NR Left-sided ulcerative colitis was refractory to standard
medical treatments (5-amino salicylic acid,
methylprednisolone and azathioprine); improvements and
clinical remission observed with HBOT after 2 weeks of
treatment; remission lasted for at least 6 months
Hulagu et al.
1997 [52],
Turkey
Case
report
1/1 2.0 ATA 100% oxygen; 2 h
duration; 1 treatment per
day for 30 days
none Patient had ulcerative pancolitis; exacerbation was
refractory to standard medical treatments (mesalazine and
total parenteral nutrition); by third week of HBOT, “definite
improvement” observed
Karkumov et
al. 1991 [53],
Bulgaria
Case
series††
34/34 10-12 treatments at 60-75
min; other parameters not
reported
NR All patients had chronic ulcerohemorrhagic colitis; all
patients improved after first 5-6 treatments
Kuroki et al.
1998 [54],
Japan
Case
report
1/1 2 ATA; 60 min duration; 1
treatment per day; 27 days
none Patient had refractory ulcerative colitis and toxic
megacolon (failed antibiotics and intravenous
prednisolone); IL-6 dropped from 13.2 to 7.2 pg/ml after 1
HBOT session; significant clinical improvements after third
day of HBOT
NR not reported
† contained patient(s) from a previous study
†† only the abstract was in English
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[79,80]. A number of studies have reported improve-
ments using stem cells in some patients with Crohn’s
disease [81-86] or ulcerative colitis [84]. Interestingly,
some animal studies report that the use of HBOT com-
bined with stem cells was more effective than stem cells
alone [87-90]. Therefore, HBOT may help lower inflam-
mation in patients with IBD through the increased
mobilization of stem cells.
Animal models of IBD demonstrate that the GI
mucosa develops hypoxia [91]. Hypoxia has been
reported to increase oxidative stress and inhibit mito-
chondrial function [92] as well as increase inflammation
[93]. Chronic inflammation can lead to tissue edema
and impaired oxygen extraction from the blood into tis-
sue [94] and a vicious cycle between hypoxia and
inflammation can therefore ensue [95]. Hypoxia also
causes an increase in hypoxia-inducible transcription
Table 3 Studies of HBOT in animal models of experimentally-induced colitis
Author, year,
country
Animal
used
Number
of
animals
HBOT parameters Comments/outcomes
Akin et al. 2002
[55], Turkey
Rat 42 2.0 ATA 100% oxygen; 2 h
treatments for 2 (acute) or 14
(chronic) days
HBOT studied in acute (2 days) and chronic (14 days) colitis; compared
to sham treatment, HBOT significantly ameliorated macroscopic, but
not microscopic, damage in chronic colitis but not acute colitis; HBOT
also significantly reduced myeloperoxidase activity (an index of the
accumulation of neutrophils) in acute colitis and decreased plasma
carbonyl content (a marker of oxidative damage) in chronic colitis
Altinel et al.
2011 [56],
Turkey
Rat 40 2.8 ATA 100% oxygen; 90 min
treatments; 2 treatments per day for
5 days
Compared to sham treatment, HBOT significantly reduced the severity
of colitis as measured by a histopathological score; HBOT also
significantly reduced malondialdehyde (a marker of oxidative stress)
and neopterin (a marker of cell-mediated immune activation).
Atug et al.
2008 [57],
Turkey
Rat 48 2.0 ATA 100% oxygen; 75 min in
duration; 2 treatments per day for
up to 3 days
Compared to sham treatment, HBOT significantly decreased colitis on
microscopic, macroscopic and tissue weight testing; HBOT also
significantly decreased myeloperoxidase activity; HBOT was equivalent
to dexamethasone in anti-inflammatory effect
Ercin et al.
2009 [58],
Turkey
Rat 36 2.4 ATA 100% oxygen; 1 h duration;
2 treatments per day for 7 days
Compared to sham treatment, HBOT significantly decreased colitis on
both microscopic and macroscopic testing compared to control group
and prevented weight loss; HBOT also significantly reduced nitric oxide
levels
Gorgulu et al.
2006 [59],
Turkey
Rat 50 2.8 ATA 100% oxygen; 90 min
duration; 2 treatments per day for 3
days
Compared to sham treatment, HBOT significantly reduced
histopathologic score of inflammation; HBOT slightly reduced
myeloperoxidase activity but not significantly
Gulec et al.
2004 [60],
Turkey
Rat 36 2.5 ATA; 90 min duration; 2
treatments per day for 5 days
HBOT significantly reduced malondialdehyde levels in erythrocytes,
plasma and intestinal tissue; HBOT significantly increased glutathione
peroxidase and superoxide dismutase levels; HBOT significantly
improved histopathological scores
Guven et al.
2009 [61],
Turkey
Rat 30 2.8 ATA 100% oxygen; 90 min
duration for 3 days
HBOT significantly reduced malondialdehyde levels, nitric oxide levels,
TNF-alpha levels, and protein carbonyl content; HBOT significantly
increased glutathione peroxidase and superoxide dismutase levels;
HBOT significantly reduced histological evidence of intestinal injury
Guven et al.
2010 [62],
Turkey†
Rat 40 2.8 ATA 100% oxygen; 90 min
duration; 2 treatments per day for 4
days
HBOT reduced malondialdehyde levels (non-significantly); HBOT
decreased inflammation and edema compared to controls
Nandi et al.
2010 [63], USA
Rat NR 2.3 ATA 100% oxygen; 1 h duration
for 2-5 days
HBOT significantly decreased indomethacin-induced ulceration and
reduced TNF-a, IL-1b, nitric oxide, nitric oxide synthase levels as well
as myeloperoxidase activity
Rachmilewitz et
al. 1998 [64],
Israel
Rat 56 2.4 ATA 100% oxygen; 1 or 7 days in
duration
HBOT significantly decreased colonic tissue weight, myeloperoxidase
levels, Prostaglandin E2 generation and nitric oxide synthase activity;
HBOT significantly decreased colitis on histological examination
Simsek et al.
2011 [65],
Turkey††
Rat 20 2.5 ATA 100% oxygen; 60 min
duration
HBOT significantly decreased intestinal injury as measured by an
apoptosis score and significantly increased protein carbonyl content
Yang et al.
2006 [66], USA
Rat 48 2.3 ATA 100% oxygen; 60 min
duration; 1-2 treatments per day for
2 or 5 days
HBOT significantly decreased TNF-a and IL-1b; HBOT significantly
reduced intestinal ulceration; HBOT significantly reduced
myeloperoxidase and nitric oxide synthase activities
NR not reported
† publication was only in abstract form
†† only the abstract was in English
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cascade [96,97]. In fact, HIF is essential for inflamma-
tion mediated by myeloid cells [98] and rats null for
HIF demonstrate almost complete inhibition of the
inflammatory response [99]. Furthermore, intestinal
biopsies from patients with IBD show elevated levels of
HIF in the mucosa [100]. Hypoxia and increased levels
of HIF can then activate nuclear factor B( N F - B)
which subsequently stimulates the production of TNF-
alpha [101]. HBOT has been shown to inhibit the
expression of HIF and its target genes [102]. Therefore,
another method whereby HBOT may lower inflamma-
tion in patients with IBD is by the relief of hypoxia and
the inhibition of HIF expression [95]. Interestingly,
decreased blood flow to the rectum has been reported
in some individuals with ulcerative colitis [8]. A reduc-
tion in tissue edema with the use of HBOT might lead
to improved blood supply and relief of hypoxia. There-
fore, HBOT may also ameliorate hypoxia and inflamma-
tion in individuals with IBD by reducing tissue edema.
Finally, the inflammation found in IBD could be sec-
ondary to an infectious agent. Since some investigators
have reported that Mycobacterium avium subspecies
paratuberculosis may play a role in IBD [7], it is possible
the HBOT may be beneficial as it has been reported to
kill Mycobacterium species [103,104]. Additional studies
investigating the effects of HBOT on inflammation and
biomarkers of inflammation in individuals with IBD are
warranted.
Effects of HBOT on oxidative stress in IBD
Some studies have reported evidence of oxidative stress
and mitochondrial dysfunction in individuals with IBD.
Several of the animal models of IBD reported a reduc-
tion in oxidative stress markers with HBOT. It should
be noted that, theoretically, HBOT might increase oxi-
dative stress through the augmented production of reac-
tive oxygen species (ROS) from the high concentration
of oxygen [105]. This may occur because increased oxy-
gen delivery to mitochondria can increase ROS produc-
tion. However, HBOT has also been shown to
upregulate the production of antioxidant enzymes such
as superoxide dismutase [106,107], glutathione peroxi-
dase [60], catalase [108], paraoxonase [109] and heme-
oxygenase 1 [110,111]. This increase in antioxidant
enzyme levels has been termed “conditioning” and can
protect against damage caused by ROS [95,112]. Two
animal models of IBD reported a significant increase in
glutathione peroxidase and superoxide dismutase levels
with HBOT [60,61], suggesting that the increased pro-
duction of antioxidant enzymes may have limited or
lowered oxidative stress in these studies. Although none
of the reviewed studies measured changes in mitochon-
drial function with HBOT, it is possible that HBOT may
have led to some improvements by augmenting mito-
chondrial function as reported in previous studies
[113-116]. Further studies examining the effects of
HBOT on oxidative stress and mitochondrial dysfunc-
tion in individuals with IBD are needed.
Effects of HBOT on IBD in human studies
The total number of identified publications utilizing
HBOT in Crohn’s disease was about twice the number
of studies in ulcerative colitis. In these studies, the num-
ber of patients treated in both diseases was similar,
although one study in ulcerative colitis reported
improvements in 34 patients, but this finding was only
reported in an English abstract, and therefore the
strengths and weaknesses of this study could not be
adequately assessed [53]. The remaining 5 studies in
ulcerative colitis only totaled 5 patients. Therefore, the
evidence in the reviewed studies for a positive effect of
HBOT is stronger for Crohn’s disease than for ulcerative
colitis.
In the studies of Crohn’sd i s e a s e ,7 8 %o ft r e a t e d
patients had an improvement with HBOT at a pressure
ranging from 2.0 to 2.8 ATA. In the studies of ulcerative
colitis, all treated patients showed improvements with a
pressure delivered at 2.0 ATA. These studies suggest
that a higher pressure may be needed to achieve these
improvements. However, because none of these studies
utilized a lower pressure of HBOT, it is not known if a
lower pressure or oxygen level would be beneficial in
IBD. However, some investigators have reported
improvements in GI function in some children with aut-
ism using HBOT at 1.3 to 1.5 ATA [117,118]. Further-
more, previous studies have reported improvements in
certain neurological conditions using hyperbaric treat-
ment at lower pressures and/or oxygen levels [119-122].
Additional studies using HBOT at varying oxygen con-
centrations and atmospheric pressures would be helpful
in determining optimal treatment protocols.
It is especially noteworthy that all of the studies on
Crohn’s disease and ulcerative colitis used HBOT in
patients who were refractory to multiple medical treat-
ments, including, in some cases, corticosteroids, 6-mer-
captopurine, mesalamine, tetracycline, 5-amino salicylic
acid, azathioprine, sulfasalazine, metronidazole, and an
elemental diet. It is possible that earlier treatment with
HBOT in individuals with IBD before severe symptoms
develop would be even more effective in ameliorating
the condition. Additional studies examining the clinical
effects of HBOT in individuals with IBD would be help-
ful in assessing this possibility.
Limitations
Many of the reviewed studies suffered from limitations,
including the lack of a control group, the open-label
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Page 7 of 11nature and the small number of participants. Some of the
studies were retrospective while only a few were prospec-
tive [10,41-43,47,49]. Most of the reviewed studies did not
report if HBOT was supplied in a monoplace or multi-
place chamber, and whether or not masks or hood systems
were used, and therefore the ability to determine the
effects of different types of chambers or oxygen delivery
systems in these studies could not be adequately assessed.
Most studies did not specifically report if there were any
adverse events. Presumably, if there had been any adverse
events, the investigators would have reported them. There-
fore, the adverse events in these studies were most likely
minimal, but since most studies did not report this, a full
assessment cannot be performed. Some of the studies may
have been limited by referral bias; for example, none of
the studies were population-based which could have
reduced potential referral bias. Another limitation of the
studies may have been publication bias where only cases
that had improvements with HBOT were published, and
cases of IBD that were treated with HBOT that did not
improve may not have been published. However, it should
be noted that for a new treatment to be recognized, it is
common for case reports to first be published to introduce
and confirm a new treatment before sufficient interest is
generated to commit resources to completing larger high-
quality, stronger studies. Since most reviewed studies had
limitations, larger studies examining the effects of HBOT
in individuals with IBD are warranted.
Conclusions
HBOT ameliorated symptoms of IBD in both human
studies and animal models. HBOT also lowered pro-
inflammatory cytokine concentrations and lowered bio-
markers of inflammation and oxidative stress. Adverse
events were minimal. Many studies suffered from limita-
tions, including possible publication and referral biases,
the lack of a control group, the retrospective nature and
a small number of participants. Additional studies are
warranted to investigate both the effects of HBOT on
biomarkers of oxidative stress and inflammation as well
as clinical outcomes in individuals with IBD.
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